bioAffinity Technologies, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $3.2M
- Price
- $0.392
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.51%
- Volume
- 340.8K
About
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
Quick stats
Shares outstanding8.1M
Computed float4.4M
Float / shares54.3%
Cash runway (months)-1.2
Key info
SectorHealthcare
IndustryMedical - Diagnostics & Research
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001712762
AI Summary
AI-generated1/50
standardbearishoffering
WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules
bioAffinity Technologies closed a $4 million private placement, issuing 8.46 million pre-funded warrants at a combined effective price of $0.4657 per unit.
Each unit includes two warrants exercisable at $0.4727 following stockholder approval, with the pre-funded warrants exercisable at $0.007.
WallachBeth Capital acted as the sole placement agent for the offering, which was conducted under Nasdaq at-the-market rules.